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Summary 
Hereditary cerebellar ataxias (CA) are neurodegenerative disorders, clinically 
characterized by a cerebellar syndrome, often accompanied by other neurological or 
non-neurological signs. All transmission modes have been described. In autosomal 
dominant forms (ADCA), mutations in more than 30 genes are implicated, but the 
molecular diagnosis remains unknown in about 40% of the cases. Implication of ion 
channels has long been an on-going topic in the genetics of CA, and mutations in 
several channel genes have been recently connected to ADCA. 
In a large family with ADCA and mild pyramidal signs, we searched for the causative 
variant with a combined approach of linkage analysis and whole exome sequencing. 
We identified a NM_018896.4:c.5144G>A mutation in CACNA1G, causing an 
arginine-to-histidine (p.Arg1715His) change in the voltage-sensor/segment S4 of the 
T-type Cav3.1 channel protein. Two out of 479 index cases screened subsequently 
harbored the same mutation. Electrophysiological experiments were performed in 
HEK293T cells to compare the properties of the p.Arg1715His and the wild-type 
Cav3.1 channels. The current-voltage and the steady-state activation curves of the 
p.Arg1715His channel were shifted positively, while the inactivation curve had a higher 
slope factor. Computer modelisation in deep cerebellar nuclei neurons suggested that 
the mutation results in decreased neuronal excitability. 
Taken together, these data establish CACNA1G, which is highly expressed in the 
cerebellum, as a gene whose mutations can cause ADCA. This is consistent with the 
neuropathological examination showing severe Purkinje cell loss. Our study further 
extends our knowledge of the link between calcium channelopathies and CA. 
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Hereditary cerebellar ataxias are rare clinically and genetically heterogeneous 
neurodegenerative disorders.1 They are characterized by a cerebellar syndrome, 
associated with other neurological or extra-neurological symptoms, and are inherited 
in all classical transmission modes. In autosomal dominant cerebellar ataxias (ADCA), 
the most frequent mutations are trinucleotide CAG repeat expansions, present in seven 
genes2, coding for a polyglutamine stretch in the corresponding proteins. Next 
mutations in frequency are noncoding nucleotide expansions and conventional 
mutations that have been described in more than 20 different genes. The causative 
variant remains unknown, however, in about 40% of individuals with ADCA.2; 3 
 
Over the last few years, next generation sequencing has led to the identification 
of an increasing number of variants in many genes implicated in this pathology.4 
Mutations in multiple genes gathered in various common pathways have highlighted 
their importance in the physiopathology of ADCAs, including channels. The first 
channel-coding gene to be involved in ADCAs was CACNA1A (MIM *601011), 
encoding the P/Q-type voltage-gated calcium channel; small polyglutamine 
expansions, loss-of-function mutations, or missense variants in this gene give rise to 
Spinocerebellar Ataxia type 6 (MIM #183086), Episodic Ataxia type 2 (MIM 
#108500), or Familial Hemiplegic Migraine type 1 (MIM #141500).5; 6 Knockdown of 
the fibroblast growth factor gene, FGF14 (MIM *601515), responsible for SCA27 
(MIM #609307), reduces calcium currents in granule cells.7 Mutations in other ion 
channel genes have also been described, including the voltage-gated potassium channel 
genes KCNC3/SCA13 (MIM *176264/#605259)8 and KCND3/SCA19-22 (MIM 
*605411/#607346),9; 10 and the ligand-gated ion channel genes ITPR1/SCA15 (MIM 
*147265/#606658) and GRID2 (MIM *602368).1; 11; 12 All these findings converge to 
emphasize the importance of ion balance, notably that of calcium ions, in cerebellar 
physiology.13 
 
In this paper, we report three pedigrees segregating ADCA, with a recurrent 
mutation inducing an amino acid change in the voltage sensor S4 segment of domain 
IV in Cav3.1, a T-type calcium channel encoded by CACNA1G (MIM *604065). We 
present electrophysiological in vitro evidence that this p.Arg1715His (NM_018896.4) 
variant alters the channel activity, shifting its steady-state activation curve towards 
more positive values and changing its inactivation slope constant. In an in silico model 
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of deep cerebellar nuclei neurons, we establish decreased excitability linked to these 
altered parameters. Altogether, we describe a monogenic disease linked to CACNA1G 
mutations; confirm the implication of Cav3.1 channels, highly expressed in Purkinje 
cells and deep cerebellar nuclei neurons, in cerebellar physiology; and strengthen the 
gathering of evidence towards the prominence of calcium levels in cerebellar ataxia 
pathophysiology. 
 
Families AAD-SAL-233, AAD-GRE-319, and AAD-SAL-454 were part of the 
Spastic Paraplegia and ATAXia (SPATAX) network cohort, along with more than 500 
other ADCA pedigrees. Affected members and relatives were examined and blood was 
taken after informed consent, according to French legislation (Paris Necker ethics 
committee approval to A. Brice and A. Durr, RBM 01-29 and RBM 03-48). All clinical 
data are summarized in Table 1. The age at onset varied widely, ranging from 9 to 78 
years; gait instability was the major presenting symptom (9/10). Even after decades of 
progression, the disability and symptoms remained mild to moderate, indicating stable 
cerebellar involvement. Ocular signs, including saccadic pursuit, horizontal nystagmus 
and transient diplopia, were often noted (7/10). Interestingly, pyramidal signs, ranging 
from reflex pyramidal syndrome to spastic gait, were present in 5/10 individuals. Of 
note, depression was reported in 3/10 individuals, and cognitive impairment in 2/10. 
When performed (n=5), MRI revealed predominantly vermian cerebellar atrophy and a 
normal pons (Figure S1). 
 
Individual AAD-SAL-233-14 (III-9 in Figure 2) had signed an informed 
consent for brain donation. She died at age 83. The left hemi-brain was examined, while 
samples from the right hemi-brain were frozen and kept in the brain bank GIE 
NeuroCEB (Bioresource Research Impact Factor number = BRIF BB-0033-00011), 
declared to the Ministry of Research and Higher Education as required by the French 
law. The Brain Bank has been officially authorized to provide samples to scientists 
(agreement AC-2007-5). Macroscopically, the cerebellar hemisphere and the vermis 
were respectively mildly and severely atrophic. The cerebral cortex appeared normal. 
Microscopically, the volume of the cerebellar white matter was reduced. Bergmann 
gliosis and empty baskets were evidences of loss of Purkinje cells, more prominent in 
the vermis. In the granular layer, the number of glomeruli was decreased. The cellular 
density was increased in the molecular layer, which appeared loosened (Figure 1). 
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Unusually abundant polyglycosan bodies were observed in all cerebellum layers. The 
neuronal density in the dentate nucleus was normal as was the density of myelinated 
axons in the hilus. There was no neuronal loss in the pontine nuclei. The number of 
neurons was reduced in the inferior olive, which appeared gliotic. The substantia nigra 
was normal.  
 Microscopic evidences of Alzheimer’s disease (MIM  
#104300) were also observed, with amyloid deposits in the cerebral cortex, the 
hippocampus and the basal ganglia (Thal phase 3 14). Tau positive neurofibrillary 
tangles, neuropil threads and senile plaques coronae were seen in the entorhinal cortex 
and hippocampus. Associative cortices were mildly affected and primary cortices, 
spared (Braak stage V 15).  
 
Polyglutamine and C9orf72 (MIM *614260) expansions had previously been 
excluded in all three index cases using classical procedures. Linkage analysis was 
performed in family AAD-SAL-233 (Figure S2). Six major putative loci were detected, 
with maximal multipoint LOD scores ranging from +1.579 to +2.279. Whole exome 
sequencing was performed in individuals AAD-SAL-233-15 (III-10 in Figure 2) and 
AAD-SAL-233-25 (IV-16 in Figure 2), with 85 to 87% 30x-coverage, through 
enrichment capture using the Sure Select All Exon 50Mb kit (Agilent) followed by 
2x75bp massive parallel sequencing in the Hiseq2000 sequencer (Illumina) (Table S1). 
Results were analyzed using the following criteria: effect on the coding sequence of an 
established protein-coding gene, heterozygous state in affected individual 25 and absent 
from healthy individual 15, location within the non-excluded loci, frequency under 
0.1% in public databases (dbSNP137, Exome Variant Server, EXome Aggregation 
Consortium). Sanger validation and segregation study in all family members led to the 
identification of two candidate variants: a chr10:g.95372766G>A, NM_006204.3: 
c.284G>A: p.Arg95His change in PDE6C (MIM *600827) and a chr17: 
g.48694921G>A, NM_018896.4: c.5144G>A: p.Arg1715His change in CACNA1G 
(MIM *604065) (Figure 2, Table S2). Of note, PDE6C is much more tolerant to 
missense variations than CACNA1G, as estimated by Samocha et al.,16 with an observed 
to expected ratio of 236/261.5 (Z-score 0.77), compared to 598/903.6 (Z-score 4.97) 
for CACNA1G. 
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We then screened ADCA index cases for variants in CACNA1G (n=479), 
PDE6C and genes previously involved in ADCA (n=384), with amplicon-based panel 
sequencing techniques, either with conventional PCR amplification followed by GS 
Junior (Roche) sequencing (n=95) or microfluidic PCR amplification (Fluidigm Access 
Array) followed by MiSeq (Illumina) sequencing (n=384) according to the 
manufacturers protocols (Table S3). Results were analyzed using the above-mentioned 
criteria. Two index cases, AAD-GRE-319-12 (II-2 in Figure 2), and AAD-SAL-454-
10 (III-1 in Figure 2), harbored the same CACNA1G NM_018896.4: c.5144G>A: 
p.Arg1715His variant. No recurrence of the abovementioned PDE6C variant was 
observed. All detected PDE6C variants, reported in Table S4, were present in public 
databases.  
No conventional mutations in genes previously involved in ADCA were found 
in AAD-GRE-319-12 (II-2 in Figure 2). AAD-SAL-454-10 (III-1 in Figure 2) also 
harbored a Variant of Unknown Significance (class 3 ACMG) in SPTBN2/SCA5 (MIM 
*604985/#600224), chr11: 66455764, NM_006946.2: c.6250G>A: p.Glu2084Lys, not 
located within the spectrin repeats as previously described for all SPTBN2 mutations.17 
It was reported at the heterozygous state in one individual in EVS and one other case 
in ExAC; almost all in silico prediction softwares matched to predict it to be tolerated 
(data not shown). No recurrence was observed in the other 383 index cases tested.  
Segregation of the CACNA1G c.5144G>A (p.Arg1715His) variant was 
established in two additional affected members of family AAD-GRE-319 (Figure 2). 
Other individuals harbored various CACNA1G variants (Table S5); however, their 
pathogenic effects could not be ascertained, due to the lack of affected individuals for 
segregation studies, genetic elements suggesting deleterious effects, or 
electrophysiological anomalies (Table S6). Analysis of flanking variants identified two 
homozygous variants in the CACNA1G region (chr17:g.48652875A>G and 
chr17:g.48655493A>G) in individual AAD-SAL-454-10 (III-1 in Figure 2) that were 
absent in AAD-SAL-233-25 (IV-16 in Figure 2) and heterozygous in AAD-GRE-319-
12 (II-2 in Figure 2), excluding a common founder effect for all three families.  
We hence focused on the CACNA1G variant versus the PDE6C one, because of 
strict co-segregation with the disease, absence in public databases, more concordant 
pathogenicity prediction scores, slightly higher conservation scores (Table S2), lower 
tolerance to missense variation, extremely high expression in the cerebellum,18-20 and 
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the previous implication of CACNA1A as well as other ion channels in cerebellar 
ataxias. 
 
To study the effect of the p.Arg1715His variant on the electrophysiological 
characteristics of Cav3.1, the c.5144G>A mutation was introduced into the cDNA of 
the human Cav3.1 channel (isoform 5, Uniprot O43497-1, 21) by site directed 
mutagenesis (QuickChange Lightning Site-Directed mutagenesis, Agilent 
technologies). The wild-type (WT) and mutant cDNA constructs were then transfected 
into HEK239T cells and macroscopic currents were recorded by whole-cell patch 
clamp techniques. Figure 3A shows typical recordings of the calcium current generated 
by these channels. Several differences between the WT and the p.Arg1715His channel 
were observed. Notably, the aberrant channel exhibited a significant shift of the steady-
state activation curve towards more positive membrane potential values. The half-
activation potential changed from -47.20 ± 0.65 mV (n=18) for the WT to -43.27 ± 0.73 
mV (n=16) (p<0.001) (Figure 3B). The steady-state inactivation curve was also 
affected. Although the half-inactivation potential was unchanged (-70.91 ± 0.48 mV 
[n=15] for the WT vs 70.68 ± 0.36 mV [n=16] for p.Arg1715His), the slope factor was 
significantly higher for the aberrant channel (5.39 ± 0.11 mV (n=16) compared to 4.29 
± 0.07 mV (n=15) for the WT, p<0.0001). As a consequence, the window current also 
shifted towards more positive membrane potentials (Figure 3D). No significant change 
was observed in current density or other biophysical properties of the channel, such as 
activation and inactivation kinetics (Figure 3E-F), recovery from inactivation (Figure 
3G) or deactivation kinetics (Figure 3H). T-type calcium channels, especially Cav3.1, 
are highly expressed in cerebellar neurons, including deep cerebellar nuclear (DCN) 
neurons22. To determine the functional consequences that the p.Arg1715His change 
could have on firing, we used a DCN computer model23, with both excitatory and 
inhibitory inputs from 150 mossy fibers and 450 Purkinje cell synapses respectively. 
Introduction of our experimental parameters for the steady state activation and 
inactivation curves in this model revealed alteration of DCN firing properties. Notably, 
the p.Arg1715His change led to a diminution of the number of spikes per burst (4 spikes 
compared to 5 for the WT, Figure 3I) and a delayed onset of burst firing, thus increasing 
the interval between the bursts (Figure 3I). These results suggest that the p.Arg1715His 
channel is responsible for a decrease in the neuronal excitability. 
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The Cav3.1 channel belongs to the family of voltage-gated calcium channels 
(VGCCs), a large family divided in two main subgroups: (i) low-voltage activated 
(LVA) VGCCs, also known as T-type, comprising the Cav3.1 encoded by CACNA1G, 
Cav3.2, and Cav3.3 isoforms; and (ii) high-voltage activated (HVA) VGCCs, further 
divided into L-type, P/Q-type, N-type and R-type depending on their sensitivity to 
pharmacological agents.24-26 VGCCs are major actors regulating the calcium entry into 
neurons, and in turn play predominant roles in membrane potential regulation, and also 
in the modulation of calcium signaling pathways, such as neurite outgrowth,27 calcium-
dependent gene transcription, neurotransmitter release, or regulation of enzymes such 
as protein kinase C,26 whose gamma subunit is associated with Spinocerebellar Ataxia 
14 (MIM #605361) when mutations occur in PRKCG (MIM *176980).28 The variety 
of coexisting subtypes and isoforms allows the establishment of highly specific 
neuronal firing patterns.26; 29; 30 
 
T-type Cav3 calcium channels differ from HVA-VGCCs by their ability to be 
activated and inactivated at low voltages, near the resting membrane potential, their 
faster recovery from inactivation, their slower deactivation, and a characteristic window 
current occurring in the range of the resting membrane potential of neurons.31; 32 In this 
respect, they act as pacemakers and excitability regulators,26 allowing cells to be 
depolarized at needed membrane potential for other channels’ activation. This window 
current is also essential for the regulation of the intracellular calcium concentration.33 
In neurons, they have two essential behaviors: triggering of a burst action potential 
following a low threshold calcium spike25; 32 and rebound burst firing.26; 31; 32 Of the 
three Cav3 isoforms, Cav3.1 is highly expressed in cerebellar neurons, as well as 
thalamic relay neurons,18; 20 where it plays a major role in the establishment of the slow 
(<1Hz) sleep oscillations of non-rapid eye movement sleep (REM).31 Gain-of-function 
variants are thought to participate in the spike-and-wave discharges of thalamocortical 
neurons in absence epilepsy through enhancement of thalamic oscillatory activities.18; 
25; 34; 35 
 
In the cerebellum, a comprehensive study of Cav3 isoforms expression in 
neurons revealed that their specific patterns are correlated to various 
electrophysiological phenotypes.30 In situ hybridization studies described CACNA1G 
mRNA in both Purkinje cells (PC) and deep cerebellar nuclei neurons (DCN).20; 36 In 
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DCN, Cav3.1 is predominantly expressed in a subset of large neurons exhibiting a 
strong ability to generate rebound burst firing after hyperpolarization.30; 37 
Pharmacological evidences confirmed that these rebound bursts are mediated by T-type 
calcium channels.38 They appear to be physiologically relevant and consistent with a 
response to inhibitory input from PCs.39 Their characteristics result from interplay 
between T-type channels and hyperpolarization-activated cyclic-nucleotide channels 
(HCN).22; 39 In PC, all three subtypes of Cav3 are expressed.30 Cav3.1 was found at the 
cell body as well as at the synapse between parallel fibers (PF) and PC19. At this 
synapse, Cav3 channels interact with intermediate conductance calcium-activated 
potassium channels (IKCa) to suppress the temporal summation of background 
excitatory postsynaptic potentials from PF through an after hyperpolarization.22; 40 This 
is essential to allow the detection of sensory-relevant high frequency inputs.22; 40 
Finally, PC burst firing was shown to rely on P/Q-type calcium current. In addition, T-
type channels interact with large conductance calcium-activated potassium channels 
(BK) to determine firing rate, burst duration and interburst interval.41 Therefore, T-type 
channels, Cav3 isoforms, and, more specifically, the Cav3.1 isoform, have major roles 
in the PF-PC-DCN signal processing. Of note, histologically, the neuronal density 
appeared normal in the dentate nucleus of our affected case; marked PC loss was 
observed. 
 
In mice, that show 93% Cav3.1 amino-acid sequence identity with humans, no 
spontaneous Cacna1g mutations have been reported; however, several models have 
been generated. Cacna1g null mice have no overt neurological phenotype, normal 
growth and normal brain pathology;42 in particular, they have no motor defects.43 
However, they present with a non-REM sleep disturbance,44 are resistant to 
pharmacologically induced absence seizures,42 show attenuated neuropathic pain,45 and 
present bradycardia and slowed atrioventricular conduction.46 The only cerebellar 
anomaly linked to Cacna1g inactivation was a loss of Purkinje cells in double mutant 
mice lacking both Cav3.1 and the alpha1 GABA-A receptor.43 In this mouse model, 
motor defects, including tremor, were exacerbated compared to mice lacking only the 
GABA-A receptor. Conversely, transgenic mice overexpressing Cav3.1 show 
spontaneous spike-and-wave discharges associated with behavioral arrest.18  
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In human pathology, the role of T-type VGCCs has only been partially 
elucidated. In particular, no monogenic disease has clearly been linked to T-type 
channel gene mutations until now.25; 47 CACNA1H (MIM *607904)/Cav3.2 is 
implicated in absence epilepsy (MIM #611942),48-50 with several mutations leading to 
increased activity of the channel51. However, in many cases, the variant rather induces 
susceptibility to seizures rather than has a monogenic causative effect.25; 49 As for 
CACNA1G, some variants have been described in Idiopathic Generalized Epilepsy 
(MIM %600669);52 many if not all of them appear to be risk factor variants and not 
causative mutations. CACNA1G was also associated with autism spectrum disorder 
(MIM %209850), but the association was too weak to fully explain the odds ratio.53 
Finally, a large study on intellectual disability identified a homozygous CACNA1G 
frameshift variant in three siblings with associated cataracts, but no reported cerebellar 
ataxia.54  
 
Despite its predominant expression in PC and DCN neurons, CACNA1G was 
never implicated by itself in cerebellar dysfunction. In three independent ADCA 
families, we describe the recurrent p.Arg1715His variant in Cav3.1. There are strong 
genetic arguments in favor of the deleteriousness of this variant: 1/ concordance of all 
in silico pathogenicity predictions; 2/ absence in all examined public databases (more 
than 60k exomes); 3/ amino acid conservation in all orthologs, paralogs, and S4 
segments of all four domains of the protein; 4/ location within a putatively linked locus 
(Figure S2); 5/ absence of pathogenic variants in all genes previously involved in 
ADCA; 6/ recurrence of the mutation in three pedigrees with exclusion of a common 
founder effect; 7/ perfect segregation in both pedigrees where it could be verified; and 
8/ location within a functionally important domain of the protein, the voltage sensor S4 
segment. Importantly, in vitro studies showed that the variant altered 
electrophysiological characteristics of the channel, with activation at more positive 
voltages, an increased slope factor of the steady-state inactivation curve and, 
consequently, a shift of the window current towards more positive potentials. Minimal 
alterations in T-type VGCC properties can lead to marked alterations in firing 
dynamics.55 Simulation of a DCN neuron activity carrying either WT or p.Arg1715His 
Cav3.1 parameters also revealed a difference in burst firing, suggesting a reduced 
neuronal excitability caused by the aberrant channel. As activity of the cerebellar DCN 
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and PC neurons is involved in movement behavior,56; 57 our findings suggest that the 
p.Arg1715His change of Cav3.1 could affect motor control by altering DCN activity.  
 
All together, these elements establish CACNA1G mutations as a monogenic 
cause of ADCA, with a recurrence of the p.Arg1715His variant and a relatively high 
frequency of almost 0.6%, in our cohort, after exclusion of polyglutamine expansions 
(~0.3% of all ADCA). The other variants detected (Table S5) could be either benign 
polymorphisms, variants that potentiate other ion channel variants such as loss-of-
function CACNA1A mutations, or causative mutations. Further investigations will be 
needed to elucidate their effects.  
 
Interestingly, the clinical picture in the families we describe does not include 
any form of epilepsy. Indeed, the p.Arg1715His variant induces a shift of activation 
towards positive voltages, while epilepsy-associated T-type channel variants are 
classically associated with a gain-of-function, through faster activation, negative shift 
of steady-state activation/inactivation properties, or increased protein expression.25; 51 
In agreement with these observations, CACNA1G KO mice are resistant to induced 
seizures.42 Expectedly, a positive shift in activation properties, as in our families, should 
be protective or have no effect.  
 
It is of note that, in family AAD-SAL-233, individual 14 (III-9 in Figure 2) 
presented with both clinical signs and pathology characteristic of Alzheimer’s disease 
(AD). Another family member presented with ataxia and Alzheimer’s type dementia, 
but no DNA was available for sequencing and the brain was not available. 
Downregulation of CACNA1G and Cav3.1 inhibition were recently correlated, in 
microarrays of human tissue, mice, and cellular models, with altered APP processing, 
and consequently, occurrence of AD.58 We could not determine whether the 
p.Arg1715His change was related to AD in this case. Nevertheless, the co-occurrence 
of AD at age 83 is not unexpected. 
 
It is interesting to notice that the variant we describe, p.Arg1715His, is 
modifying a highly conserved arginine in the S4 segment of the domain IV of the 
channel. All T-type channels share a common general membrane topology with four 
domain repeats, each including six transmembrane segments (S1 to S6). S4 segments, 
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through their positive arginine residues, are considered the voltage sensing elements, 
and their alteration is expected to affect the voltage dependency of the channel. A 
systematic mutagenesis study in Cav3.1 showed that loss of the outermost arginine 
residues in the voltage sensor S4 segment of domain IV affects the steady-state 
inactivation curve.59 Our results establish that Arg1715, the third outermost arginine in 
domain IV (R3), also plays a role in Cav3.1 gating by shifting the steady-state activation 
curve and changing the slope of the steady-state inactivation curve. This is consistent 
with the observation, in Cav3.2, that the equivalent arginine to histidine change (R3), 
also induces a positive shift in the steady-state activation curve of the protein at pH6.5,60 
what would be expected when eliminating one of the segment S4 arginines.  
 
In conclusion, we report three ADCA families in which a common variant 
affecting an arginine residue in the voltage sensor S4 segment of domain IV in Cav3.1 
segregates with the disease. Genetic and electrophysiological evidence support the 
pathogenicity of this variant. These results underscore the prominent role of Cav3.1-
mediated calcium currents in the cerebellar physiology, while previous reports on 
dysfunctions of this channel focused on thalamocortical relay neurons. We describe a 
monogenic disease caused by T-type current alteration. Our results also underscore the 
important role played by segment S4 of domain IV in the gating properties of Cav3.1. 
Finally, we provide further evidence of the importance of ion channel function in the 
physiopathology of cerebellar ataxia, and, in particular, of calcium-related pathways.  
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Table 1. Clinical characteristics of affected individuals from families AAD-SAL-233, AAD-GRE-319, and AAD-SAL-454 
    
Individua
l N°*  
(sex) 
AAD-
SAL-
233-9, 
III-3 (F) 
AAD-
SAL-233-
14, 
III-9 (F) 
AAD-
SAL-233-
20, 
IV-4 (M) 
AAD-SAL-233-25, 
IV-16 (F) 
AAD-SAL-233-45, 
V-5 (F) 
AAD-
SAL-233-
46, 
V-6 (F) 
AAD-GRE-319-12, 
II-2 (F) 
AAD-
GRE-
319-13, 
III-2 (M) 
AAD-
GRE-
319-14, 
II-1 (F) 
AAD-SAL-454-10, 
III-1 (M) 
Age at 
exam 
(years) 
73 
(1998) 
82 (2012) 43 (1999) 42 (1999) 53 (2012) 
28 
(2001) 
39 (2012) 32 (2009) 57 (1998) 
69 
(2012) 
72-74 
(2013-
2015) 
51 (2015) 
79 
(2015) 
37 
(2000) 
47 (2010) 
Age at 
onset 
(years) 
20 68 41 9 19 18 37 40 78 30 
Disease 
duration 
(years) 
53 14 2 33 41 9 20 18 20 32 35-37 11 1 7 17 
Symptom
s at onset 
Vertigo 
Gait 
instability 
Gait 
instability 
Gait instability, vertigo Gait instability 
Gait 
instability 
Gait instability 
Gait 
instability 
Gait 
instabili
ty 
Gait instability 
Disability 
score 
4/7 4/7 1/7 3/7 3/7 2/7 2/7 2/7 4/7 5/7 5/7 3/7 2/7 2/7 3/7 
Cerebella
r 
syndrome 
(SARA 
score) 
Modera
te 
Yes Mild Mild 
Yes 
(20/40) 
Yes 
Mild 
(12.5/40) 
Mild Yes 
Yes 
(21/40) 
20.5/40 12/40 4/40 Yes 
Yes 
(12/40) 
Cerebella
r signs 
UL 
Yes NA No No Yes No Yes Yes No Mild Mild Mild No No Yes 
Dysarthri
a 
Severe No Yes Yes Yes No Yes Yes Yes 
Moderat
e 
Moderate Moderate No Yes Yes 
 15 
Ocular 
signs 
Limited 
upward 
gaze 
NA None 
Intermitte
nt 
diplopia  
Hypo 
metric 
saccades, 
square 
waves 
Saccad
ic 
pursuit 
Hypometr
ic 
saccades 
None 
Saccadic 
pursuit 
Saccadic 
pursuit 
Saccadic 
pursuit, 
diplopia,  
strabism 
Saccadic 
pursuit 
Saccadi
c 
pursuit 
Nystagm
us 
Nystagmu
s 
LL 
reflexes 
+ 
(Ankle-
) 
NA ++ ++ ++ + + N + N + N N N N 
Spastic 
gait 
No NA Mild Mild Mild   No No   No Mild No No No No 
UL 
reflexes 
N NA ++ ++ ++ N + N + N + N N N N 
Babinski 
sign 
No NA No Yes Yes No No No Unilateral No No No No Yes No 
Decreased 
vibration 
sense at 
ankles 
Yes NA Yes No No No Yes No No Mild Mild No Mild No Yes 
Urinary 
symptoms 
Urgenc
y 
NA No No 
Incontinen
ce 
No No No No No Urgency 
No; 
erectile 
dysfuncti
on 
Urgency Urgency 
Incontinen
ce 
Other 
Signs 
No NA No 
No 
(Myokym
ia 
orbicular) 
Postural  
UL and 
head 
tremor 
No No 
No 
(Myokym
ia 
orbicular) 
Scoliosis, 
Swallowi
ng 
difficultie
s 
Myokym
ia 
orbicular 
Dysphagia, 
dysarthria  
Dysphagi
a, 
dysarthria 
No No 
Swallowin
g 
difficulties
, Psoriasis 
Mood or 
Cognitive 
impairme
nt 
No 
Alzheime
r's disease 
Depression 
Depressio
n 
No No N No No No No No No 
MMS 
25/30, 
Depressi
on 
No 
 16 
Cerebral 
MRI 
NA NA 
Vermian 
atrophy 
less 
foliation of 
the 
hemispher
es, N-
acétyl-
aspartate 
decrease 
Vermian 
atrophy 
NA 
Vermia
n 
atrophy 
NA NA 
Vermian 
atrophy 
NA 
Cerebellar 
atrophy 
(vermian+
+), white 
matter 
hypersigna
ls 
NA NA 
Vermian 
Atrophy 
Cerebellar 
and 
brainstem 
hypoplasia 
and 
atrophy 
F: female 
M: male 
NA: not available 
LL: lower limbs 
UL: upper limbs 
N: normal 
MMS: mini mental state 
MRI: magnetic resonance imaging 
SDFS score: Spinocerebellar Degeneration Functional Score 
 0: no functional handicap; 1: no functional handicap but signs at examination; 2: mild, able to run; 3: moderate, unable to run; 4: severe, 
walking with one stick, unlimited walking; 5: walking with two sticks; 6: unable to walk, requiring a wheelchair; 7: bedridden 
SARA score: Scale for the Assessment and Rating of Ataxia 
 
*Personal numbers are followed by pedigree numbers according to figure 2. 
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Figure 1. Neuropathologic examination of the cerebellum of individual AAD-SAL-
233-14 (III-9 in Figure 2) 
 
(A - B) Case; (C - D) Control. Hematoxylin and eosin staining. 
(A and C) Granular layer of the cerebellum. The black arrows in (C) point to normal 
glomeruli; normal glomeruli cannot be identified in (A). 
(B and D) Purkinje cell layer. Four normal Purkinje cells are visible in (D), one of 
which is indicated by a black arrow; Purkinje cell loss is severe in (B), only the 
processes of the basket cells are visible ("empty baskets", black arrows). Note the 
additional layer composed of Bergmann glia (white arrows). The asterisk in (B) and 
(D) indicates the molecular layer, which appears loosened in (B). 
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Figure 2. Segregation of the p.Arg1715His change in ADCA pedigrees and 
alignment of orthologs and paralogs 
 
(A) Pedigrees of ADCA families with the p.Arg1715His change. Number of affected 
individuals tested: six in AAD-SAL-233, three in AAD-GRE-319, one in AAD-SAL-
454. All affected but no unaffected individuals harbor the variant in the heterozygous 
state. 
(B) Chromatograms showing the mutation in individuals AAD-SAL-233-9 (III-3), 
AAD-GRE-319-12 (II-2), and AAD-SAL-454-10 (III-1). 
(C) Schematic representation of Cav3.1, showing its organization in four domains, each 
containing six transmembrane segments; segment S4 contains many positively charged 
aminoacids, such as arginine, and is therefore the voltage-sensor. The p.Arg1715His 
change is located in segment S4 of domain IV. Alignment of orthologs (D) and paralogs 
(E) shows that the arginine residues in Cav3.1 are very highly conserved across all 
species, T-type channels, and domains.  
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Figure 3. Electrophysiological analysis of WT and p.Arg1715His Cav3.1 calcium 
channels 
 
(A) Current traces obtained with wild-type (WT) and p.Arg1715His channels at various 
membrane potentials (-90, -80, -70, -65, -60, -55, -50, -45, -40, -35, -30, -25, -20 mV) 
and from a holding potential of -100mV. Notice the trace in red (-50mV), which shows 
a smaller current for the pArg1715His channel (36% of the maximum current compared 
with 54% for the WT) 
(B) Averaged current-voltage relationships from traces in panel A. The normalized 
conductance-voltage curve fitted with a Boltzman equation: I/Imax=Gmax(Vm-
Erev)/(1+exp(V1/2-Vm)/k) for each individual cell.  
(C) Steady-state inactivation curves. The curves were fitted using 
I/Imax=1/(1+exp(Vm—V1/2)/k)  
(D) Availability of calcium currents (mean steady-state activation and inactivation 
curves). The steady-state activation curves were fitted with a Boltzmann equation 
G/Gmax=1/(1+exp(V1/2-Vm)/K) were G was calculated as follows: G=I/(Vm-Erev).  
(E and F) Time-constant of inactivation (τ inact) and activation (τ act) kinetics. The 
values were obtained by fitting the traces showed in panel A with a double exponential 
function. 
(G) Recovery from short-term inactivation using a two paired-pulse protocol  
(H) Deactivation kinetics (τ deact).   
(I) Simulation of a DCN neuron firing using the steady state activation and inactivation 
values obtained for the WT (black) and the p.Arg1715His (red) channels. The DCN 
model used was developed by Luthman et al.23 using the NEURON simulation 
environment (https://www.neuron.yale.edu/neuron/), based on the model originally 
implemented in GENESIS by Steuber et al.61 The NaP, HCN and CaLVA conductances 
were changed to match the “Neuron 1” model described by Steuber et al.61  
In the above-mentioned equations, V1/2 represents either the half-activation 
potential (steady-state activation curve) or the half-inactivation potential (steady-state 
inactivation curve). Other parameters are Vm, membrane potential; Erev, reversal 
potential; k, slope factor; G, conductance; Gmax, maximum conductance; I, current at 
a given Vm; Imax, maximum current. The extracellular solution contained (in mM): 
135 NaCl, 20 TEACl, 2 CaCl2, 1 MgCl2, 10 HEPES, pH adjusted to 7.44 with KOH. 
Patch pipettes were filled with an internal solution (140 mM CsCl, 10 mM EGTA, 3 
 20 
mM CaCl2, 10 mM HEPES, 3 mM Mg-ATP, 0.6 mM GTP, pH adjusted to 7.25 with 
KOH) and had a typical resistance of 2-3MΩ. From B to H: WT values are represented 
with black circles and p.Arg1715His with red squares. Data are represented as mean ± 
SEM. 
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Web Resources 
The URLs for data presented herein are as follows: 
dbSNP137, http://www.ncbi.nlm.nih.gov/projects/SNP 
Exome Aggregation Consortium, http://exac.broadinstitute.org 
Exome Variant Server, http://evs.gs.washington.edu/EVS/ 
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org 
Scale for the Assessment and Rating of Ataxia, http://www.ataxia-study-
group.net/html/about/ataxiascales/sara/SARA.pdf 
SPATAX, https://spatax.wordpress.com/ 
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Table 1. Clinical characteristics of affected individuals from families AAD-SAL-233, AAD-GRE-319, and AAD-SAL-454 
    
Individua
l N°*  
(sex) 
AAD-
SAL-
233-9, 
III-3 (F) 
AAD-
SAL-233-
14, 
III-9 (F) 
AAD-
SAL-233-
20, 
IV-4 (M) 
AAD-SAL-233-25, 
IV-16 (F) 
AAD-SAL-233-45, 
V-5 (F) 
AAD-
SAL-233-
46, 
V-6 (F) 
AAD-GRE-319-12, 
II-2 (F) 
AAD-
GRE-
319-13, 
III-2 (M) 
AAD-
GRE-
319-14, 
II-1 (F) 
AAD-SAL-454-10, 
III-1 (M) 
Age at 
exam 
(years) 
73 
(1998) 
82 (2012) 43 (1999) 42 (1999) 53 (2012) 
28 
(2001) 
39 (2012) 32 (2009) 57 (1998) 
69 
(2012) 
72-74 
(2013-
2015) 
51 (2015) 
79 
(2015) 
37 (2000) 47 (2010) 
Age at 
onset 
(years) 
20 68 41 9 19 18 37 40 78 30 
Disease 
duration 
(years) 
53 14 2 33 41 9 20 18 20 32 35-37 11 1 7 17 
Symptom
s at onset 
Vertigo 
Gait 
instability 
Gait 
instability 
Gait instability, vertigo Gait instability 
Gait 
instability 
Gait instability 
Gait 
instability 
Gait 
instabilit
y 
Gait instability 
Disability 
score 
4/7 4/7 1/7 3/7 3/7 2/7 2/7 2/7 4/7 5/7 5/7 3/7 2/7 2/7 3/7 
Cerebella
r 
syndrome 
(SARA 
score) 
Modera
te 
Yes Mild Mild 
Yes 
(20/40) 
Yes 
Mild 
(12.5/40) 
Mild Yes 
Yes 
(21/40) 
20.5/40 12/40 4/40 Yes 
Yes 
(12/40) 
Cerebella
r signs 
UL 
Yes NA No No Yes No Yes Yes No Mild Mild Mild No No Yes 
Dysarthri
a 
Severe No Yes Yes Yes No Yes Yes Yes Moderate Moderate Moderate No Yes Yes 
 15 
Ocular 
signs 
Limited 
upward 
gaze 
NA None 
Intermitte
nt 
diplopia  
Hypo 
metric 
saccades, 
square 
waves 
Saccadi
c 
pursuit 
Hypometr
ic 
saccades 
None 
Saccadic 
pursuit 
Saccadic 
pursuit 
Saccadic 
pursuit, 
diplopia,  
strabism 
Saccadic 
pursuit 
Saccadi
c pursuit 
Nystagm
us 
Nystagmus 
LL 
reflexes 
+ 
(Ankle-
) 
NA ++ ++ ++ + + N + N + N N N N 
Spastic 
gait 
No NA Mild Mild Mild   No No   No Mild No No No No 
UL 
reflexes 
N NA ++ ++ ++ N + N + N + N N N N 
Babinski 
sign 
No NA No Yes Yes No No No Unilateral No No No No Yes No 
Decreased 
vibration 
sense at 
ankles 
Yes NA Yes No No No Yes No No Mild Mild No Mild No Yes 
Urinary 
symptoms 
Urgenc
y 
NA No No 
Incontinen
ce 
No No No No No Urgency 
No; 
erectile 
dysfuncti
on 
Urgency Urgency 
Incontinen
ce 
Other 
Signs 
No NA No 
No 
(Myokym
ia 
orbicular) 
Postural  
UL and 
head 
tremor 
No No 
No 
(Myokym
ia 
orbicular) 
Scoliosis, 
Swallowi
ng 
difficultie
s 
Myokym
ia 
orbicular 
Dysphagia, 
dysarthria  
Dysphagi
a, 
dysarthria 
No No 
Swallowin
g 
difficulties
, Psoriasis 
Mood or 
Cognitive 
impairme
nt 
No 
Alzheime
r's disease 
Depression 
Depressio
n 
No No N No No No No No No 
MMS 
25/30, 
Depressi
on 
No 
 16 
Cerebral 
MRI 
NA NA 
Vermian 
atrophy 
less 
foliation of 
the 
hemispher
es, N-
acétyl-
aspartate 
decrease 
Vermian 
atrophy 
NA 
Vermia
n 
atrophy 
NA NA 
Vermian 
atrophy 
NA 
Cerebellar 
atrophy 
(vermian+
+), white 
matter 
hypersignal
s 
NA NA 
Vermian 
Atrophy 
Cerebellar 
and 
brainstem 
hypoplasia 
and 
atrophy 
F: female 
M: male 
NA: not available 
LL: lower limbs 
UL: upper limbs 
N: normal 
MMS: mini mental state 
MRI: magnetic resonance imaging 
SDFS score: Spinocerebellar Degeneration Functional Score 
 0: no functional handicap; 1: no functional handicap but signs at examination; 2: mild, able to run; 3: moderate, unable to run; 4: severe, 
walking with one stick, unlimited walking; 5: walking with two sticks; 6: unable to walk, requiring a wheelchair; 7: bedridden 
SARA score: Scale for the Assessment and Rating of Ataxia 
 
*Personal numbers are followed by pedigree numbers according to figure 2. 
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Figure 1. Neuropathologic examination of the cerebellum of individual AAD-
SAL-233-14 (III-9 in Figure 2) 
 
(A - B) Case; (C - D) Control. Hematoxylin and eosin staining. 
(A and C) Granular layer of the cerebellum. The black arrows in (C) point to normal 
glomeruli; normal glomeruli cannot be identified in (A). 
(B and D) Purkinje cell layer. Four normal Purkinje cells are visible in (D), one of 
which is indicated by a black arrow; Purkinje cell loss is severe in (B), only the 
processes of the basket cells are visible ("empty baskets", black arrows). Note the 
additional layer composed of Bergmann glia (white arrows). The asterisk in (B) and 
(D) indicates the molecular layer, which appears loosened in (B). 
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Figure 2. Segregation of the p.Arg1715His change in ADCA pedigrees and 
alignment of orthologs and paralogs 
 
(A) Pedigrees of ADCA families with the p.Arg1715His change. Number of affected 
individuals tested: six in AAD-SAL-233, three in AAD-GRE-319, one in AAD-SAL-
454. All affected but no unaffected individuals harbor the variant in the heterozygous 
state. 
(B) Chromatograms showing the mutation in individuals AAD-SAL-233-9 (III-3), 
AAD-GRE-319-12 (II-2), and AAD-SAL-454-10 (III-1). 
(C) Schematic representation of Cav3.1, showing its organization in four domains, 
each containing six transmembrane segments; segment S4 contains many positively 
charged aminoacids, such as arginine, and is therefore the voltage-sensor. The 
p.Arg1715His change is located in segment S4 of domain IV. Alignment of orthologs 
(D) and paralogs (E) shows that the arginine residues in Cav3.1 are very highly 
conserved across all species, T-type channels, and domains.  
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Figure 3. Electrophysiological analysis of WT and p.Arg1715His Cav3.1 calcium 
channels 
 
(A) Current traces obtained with wild-type (WT) and p.Arg1715His channels at 
various membrane potentials (-90, -80, -70, -65, -60, -55, -50, -45, -40, -35, -30, -25, -
20 mV) and from a holding potential of -100mV. Notice the trace in red (-50mV), 
which shows a smaller current for the pArg1715His channel (36% of the maximum 
current compared with 54% for the WT) 
(B) Averaged current-voltage relationships from traces in panel A. The normalized 
conductance-voltage curve fitted with a Boltzman equation: I/Imax=Gmax(Vm-
Erev)/(1+exp(V1/2-Vm)/k) for each individual cell.  
(C) Steady-state inactivation curves. The curves were fitted using 
I/Imax=1/(1+exp(Vm—V1/2)/k)  
(D) Availability of calcium currents (mean steady-state activation and inactivation 
curves). The steady-state activation curves were fitted with a Boltzmann equation 
G/Gmax=1/(1+exp(V1/2-Vm)/K) were G was calculated as follows: G=I/(Vm-Erev).  
(E and F) Time-constant of inactivation (τ inact) and activation (τ act) kinetics. The 
values were obtained by fitting the traces showed in panel A with a double 
exponential function. 
(G) Recovery from short-term inactivation using a two paired-pulse protocol  
(H) Deactivation kinetics (τ deact).   
(I) Simulation of a DCN neuron firing using the steady state activation and 
inactivation values obtained for the WT (black) and the p.Arg1715His (red) channels. 
The DCN model used was developed by Luthman et al.23 using the NEURON 
simulation environment (https://www.neuron.yale.edu/neuron/), based on the model 
originally implemented in GENESIS by Steuber et al.61 The NaP, HCN and CaLVA 
conductances were changed to match the “Neuron 1” model described by Steuber et 
al.61  
In the above-mentioned equations, V1/2 represents either the half-activation 
potential (steady-state activation curve) or the half-inactivation potential (steady-state 
inactivation curve). Other parameters are Vm, membrane potential; Erev, reversal 
potential; k, slope factor; G, conductance; Gmax, maximum conductance; I, current at 
a given Vm; Imax, maximum current. The extracellular solution contained (in mM): 
135 NaCl, 20 TEACl, 2 CaCl2, 1 MgCl2, 10 HEPES, pH adjusted to 7.44 with KOH. 
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Patch pipettes were filled with an internal solution (140 mM CsCl, 10 mM EGTA, 3 
mM CaCl2, 10 mM HEPES, 3 mM Mg-ATP, 0.6 mM GTP, pH adjusted to 7.25 with 
KOH) and had a typical resistance of 2-3MΩ. From B to H: WT values are 
represented with black circles and p.Arg1715His with red squares. Data are 
represented as mean ± SEM. 
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Figure S1. MRI findings in individual AAD-SAL-233-25 (IV-16 in Figure 2) 
Cerebral MRI in individual AAD-SAL-233-25 (IV-16 in Figure 2) at age 49. Sagittal view of 
a T1-weighted sequence showing superior cerebellar vermian atrophy, normal pons and 
cerebellar amygdala. 
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Figure S2. Whole genome linkage analysis in family AAD-SAL-233. 
(A) Multipoint linkage analysis on all the autosomes in AAD-SAL-233 family. Whole 
genome linkage analysis was performed using Illumina LINKAGE_12 microarrays (6090 
SNP markers). Genotypes were determined using Beadstudio (Illumina) and analyzed with 
MERLIN 1.0,1 assuming an autosomal dominant transmission under a 0.80 penetrance model 
with equal allele frequencies, similar recombination fractions between males and females, and 
a disease frequency of 0.00001. Genotypes were available for 12 individuals, including 
affected subjects 9, 14, 20, 23, 25, 45, 46 (III-3, III-9, IV-4, IV-7, IV-16, V-5 and V-6 in 
Figure 2) and their relatives, 11, 15, 21, 24, 29 (III-5, III-10, IV-5, IV-8 and IV-11 in Figure 
2). Whole genome linkage analysis could not lead to the identification of a unique well-
defined associated locus due to pedigree structure and size limitations. Instead, various 
putatively linked or unexcluded (LOD scores above -2) loci were found in the family, 
including six putatively linked loci with multipoint LOD scores reaching the maximal 
expected values of this pedigree (from +1.579 to +2.279) and various uninformative 
regions.  (B) Close-up view of the linkage analysis results for chromosome 17. A significant 
multipoint LOD score (Zmax = +2.001) was found between markers rs2058237 and 
rs792786, in a region encompassing the CACNA1G gene. 
 Supplemental Figure S3 
 
 
 
 
Figure S3. Schematics of Cav3.1 with other variants found by panel sequencing. 
Schematics of Cav3.1 with all changes linked to CACNA1G variants encompassed by panel 
sequencing. Genetic characteristics of the variants are summarized in Table S4. The 
deleterious p.Arg1715His change is shown with a bright red pentagon; Variants of Unknown 
Significance are represented with diamonds, Variants of Unknown Significance found in 
individuals otherwise presenting a CACNA1A frameshift are indicated with circles.  
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Individual 
AAD-SAL-233-15 
(III-10) 
AAD-SAL-233-25  
(IV-16) 
Number of reads 292635836 270474232 
Aligned reads 291158538 (99.50%) 268296715 (99.19%) 
Aligned but not duplicated reads 91598083 (31.30%) 95951959 (35.48%) 
Percentage of target with >30x coverage 86.57% 85.47% 
Number of variants 34226 36501 
Number of variants in exons +/-200bp 31133 33083 
 
 
Table S1. Whole exome sequencing statistics. 
The BWA software was used in order to map reads on the reference genome: Human 
reference hg19. Reads related to PCR duplicates were removed from the alignment using 
Samtools. 
Mutations were called according to the following criteria: (i) position coverage greater or 
equal to 20, ii) mutation proportion greater or equal to 25%, iii) mutated bases called at least 
10% on each strand. 
Supplemental Table S2 
 
Chrom
osome 
Position 
Refere
nce 
Altern
ative 
Gene Segregation Aminoacid change 
SIFT 
score 
Polyphen2_
HDIV 
score 
Polyphen2_
HVAR 
score 
MutationTaster 
score 
GERP++ 
PhyloP 46 
way 
Maximal 
Population 
Frequency 
1000G 
ALL 
ExAC 
All 
ExAC 
East 
Asian 
ExAC 
South 
Asian 
EVS 
All 
EVS 
African 
American 
EVS 
European 
American 
10 95372766 G A PDE6C 
present in 
all affected 
and healthy 
individual 
19 (IV-1) 
NM_006204.2: 
c.284G>A: 
p.Arg95His 
0 (D) 0.987 (D) 0.573 (P) D (1) 4.5 1.527 0.0003 . 0 0.0001 0.0002 0.0002 . 0.0003 
17 48694921 G A CACNA1G 
present in 
all affected, 
absent from 
all 
unaffected 
NM_018896.4: 
c.5144G>A: 
p.Arg1715His 
0 (D) 1 (D) 1 (D) D (1) 5.02 2.348 . . . . . . . . 
 
 
Table S2. Characteristics of AAD-SAL-233 variants. 
 Summary of characteristics for both variants segregating in family AAD-SAL-233. Annotation was performed using Annovar 
(www.openbioinformatics.org/annovar/).2 The database frequencies originate from 1000 genomes (www.1000genomes.org/), Exome Variant Server (EVS, 
http://evs.gs.washington.edu/EVS) and Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org/). Pathogenicity scores are evaluated as follows: SIFT 
(http://sift.jcvi.org/) predicts deleteriousness (D) under 0.05; Polyphen2 (http://genetics.bwh.harvard.edu/pph2/) classifies SNPs as probably damaging (D; 
HDIV>=0.957, HVAR>=0.909), possibly damaging (P; 0.453<=HDIV<=0.956, 0.447<=pp2_hdiv<=0.908), or benign (B; HDIV<=0.452, HVAR <=0.446); LRT  
differentiates variants with deleterious (D), neutral (N) or unknown (U) effect;3 MutationTaster (http://www.mutationtaster.org/) classifies them as 
"disease_causing_automatic" (A), "disease_causing" (D), "polymorphism" (N) or "polymorphism_automatic" (P) with a given probability value, 1 being the most 
probable. For both GERP++ (http://mendel.stanford.edu/SidowLab/downloads/gerp/) and PhyloP (http://compgen.bscb.cornell.edu/phast/help-pages/phyloP.txt), higher 
scores indicate better residue conservation. 
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PCRs / GSJunior (n=96) Fluidigm / MiSeq (n=384) 
Exon 
Mean coverage of 
exon (all individuals) 
Mean percentage of 
exon covered <10x 
Number of individuals with 
>=10% of exon covered 
<10x 
Mean percentage of 
exon covered >=30x 
Number of individuals with 
>=90% of exon covered 
>=30x 
Mean coverage of 
exon (all individuals) 
Mean percentage of 
exon covered <10x 
Number of individuals with 
>=10% of exon covered 
<10x 
Mean percentage of 
exon covered >=30x 
Number of individuals with 
>=90% of exon covered 
>=30x 
1 70.1 23.9 23 38.3 36 0.1 99.9 384 0 0 
2 67.8 37.9 36 43.2 41 
458.4 0.7 5 99.1580729 379 
3 75.2 0.0 0 93.7 89 
4 75.1 3.2 3 93.7 89 637.2 0.4 2 99.47916667 382 
5 52.7 17.9 17 80.0 76 670.6 0.7 3 99.05442708 380 
6 109.0 0.5 1 98.8 92 
611.6 1.2 6 98.7223958 378 
7 83.6 1.1 1 97.9 93 
8 64.6 10.5 60 77.0 3 473.9 1.1 7 98.74505208 374 
9 111.1 3.3 7 90.1 72 880.6 0.5 3 99.37604167 381 
10 62.4 11.6 11 88.4 84 497.9 1.5 5 97.62005208 379 
11 77.0 0.8 1 93.5 87 
798.8 0.8 5 99.1302083 379 12 86.0 0.7 1 90.7 76 
13 65.3 0.0 0 86.3 82 
14 47.3 3.2 3 64.2 61 53.1 6.5 53 70.33203125 217 
15 73.3 0.0 0 94.9 89 
553.9 9.8 119 82.3257812 177 
16 75.3 4.2 4 71.6 68 
17 59.2 7.8 16 72.9 39 625.9 0.8 4 98.94192708 378 
18 53.6 1.1 1 91.6 87 
711.4 1.1 6 98.8440104 378 
19 41.3 20.0 19 71.4 66 
20 93.4 0.0 0 100.0 95 
270.1 4.1 54 94.625 313 
21 40.6 7.4 7 51.9 49 
22 66.9 2.1 2 93.7 89 0.6 99.7 384 0 0 
23 53.6 0.0 0 84.9 80 379.7 0.4 2 99.47916667 382 
24 71.6 0.0 0 64.2 61 568.6 0.4 2 99.47916667 382 
25 68.5 0.0 0 92.9 87 165.5 1.3 5 97.76302083 374 
26 46.9 5.3 5 65.3 62 263.1 1.3 5 98.69791667 379 
27 30.5 12.6 12 32.8 31 74.0 1.8 7 93.37760417 349 
28 55.2 0.0 0 82.1 78 709.7 0.6 2 98.75260417 382 
29 76.4 0.0 0 93.7 89 
518.0 1.1 7 98.5570313 373 
30 90.0 1.1 1 95.8 91 
31 93.5 1.0 2 81.2 55 
32 72.2 0.0 0 92.6 88 
33 80.8 1.4 3 79.4 52 559.5 0.6 3 99.32447917 380 
34 62.8 0.0 0 93.7 89 475.3 0.4 2 99.20208333 381 
35 75.4 0.0 0 94.7 90 675.6 0.3 2 99.47916667 382 
36 59.1 0.0 0 93.4 88 353.3 1.0 4 98.95833333 380 
37 36.4 3.1 4 44.3 35 0.7 99.3 383 0.312760417 0 
38 74.1 7.9 49 80.8 24 316.4 0.7 4 99.20859375 379 
 
 
Table S3. Coverage statistics for both amplicon panels. 
For the PCRs / GSJunior panel (n=96), PCRs were performed using specific primers (available upon request), with Fast Start High Fidelity Taq (Roche Life Science) 
following the manufacturer’s protocol. Sequencing was performed with the Roche GS Junior 454 sequencing system, following the manufacturer’s protocol. 
For the Fluidigm / MiSeq panel (n=384), PCRs were performed using specific primers (Fluidigm D3 Assay Design), with Fast Start High Fidelity Taq (Roche Life 
Science), using the Fluidigm Access Array, following the manufacturer’s protocol. Sequencing was performed with the MiSeq sequencing system (2x300bp, V5), 
following the manufacturer’s protocol. 
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Comment Chromosome Position Reference Alternative Aminoacid change 
SIFT 
score 
Polyphen2_HDIV 
score 
Polyphen2_HVAR 
score 
MutationTaster 
score 
GERP
++ 
PhyloP 
46 way 
EVS 
chromosome 
count 
ExAC 
chromosome 
count 
  10 95381695 A G NM_006204.2:c.730A>G:p.Met244Val 0 (D) 0.046 (B) 0.023 (B) 0.846 (D) 3.64 2.166 G=1/A=13005 G=1/A=121365 
  10 95386461 C T NM_006204.2:c.1004C>T:p.Pro335Leu 0.02 (D) 0.996 (D) 0.732 (P) 1 (D) 4.58 2.89 T=0 T=8/C=118458 
Causative FA2H 
homozygous 
variant validated 
in the family 
10 95399849 G A NM_006204.2:c.1505G>A:p.Arg502His 0.08 (T) 0.76 (P) 0.136 (B) 1 (N) -2.12 -0.561 A=0 A=4/G=121342 
 
 
Table S4. Characteristics of other PDE6C variants found by panel sequencing. 
Summary of characteristics for all PDE6C variants found by panel sequencing in 384 individuals. Annotation was performed using Annovar 
(www.openbioinformatics.org/annovar/).2 The database frequencies originate from 1000 genomes (www.1000genomes.org/), Exome Variant Server (EVS, 
http://evs.gs.washington.edu/EVS) and Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org/). Pathogenicity scores are evaluated as follows: SIFT 
(http://sift.jcvi.org/) predicts deleteriousness (D) under 0.05; the variant was else considered tolerated (T); Polyphen2 (http://genetics.bwh.harvard.edu/pph2/) classifies 
SNPs as probably damaging (D; HDIV>=0.957, HVAR>=0.909), possibly damaging (P; 0.453<=HDIV<=0.956, 0.447<=pp2_hdiv<=0.908), or benign (B; 
HDIV<=0.452, HVAR <=0.446); MutationTaster (http://www.mutationtaster.org/) classifies them as "disease_causing_automatic" (A), "disease_causing" (D), 
"polymorphism" (N) or "polymorphism_automatic" (P) with a given probability value, 1 being the most probable. For both GERP++ 
(http://mendel.stanford.edu/SidowLab/downloads/gerp/) and PhyloP (http://compgen.bscb.cornell.edu/phast/help-pages/phyloP.txt), higher scores indicate better 
residue conservation. 
 
 
Supplemental Table S5 
Individual Chr Position Ref Alt Amino acid change 
Variant(s) in 
other genes 
involved in 
ADCA 
Sanger 
confirmation 
Segregation 
within 
family 
Electrophysiological 
evidences 
SIFT 
score 
Polyphen2_HDIV 
score 
Polyphen2_HVAR 
score 
MutationTaster 
score GERP++ 
phyloP 
46way 
Maximal 
Population 
Frequency 
1000G 
ALL 
ExAC 
ALL 
EVS 
ALL 
  Pathogenic variant (3 Strong PS1 according to ACMG guidelines, Richard et al., 2015) 
recurrent : 
AAD-SAL-
233, AAD-
GRE-319, 
AAD-SAL-
454 17 48694921 G A NM_018896:c.5144G>A:pArg1715His No Yes 
6 affected in 
AAD-SAL-
233, 3 
affected in 
AAD-GRE-
319 
statistically 
significant alterations 
of activation and 
inactivation curves 0 (D) 1 (D) 1 (D) D (1) 5.02 2.348 . . . . 
  Variants of Unknown Significance (VUS) 
H202 17 48674228 C T NM_018896:c.3202C>T:p.Arg1068Cys NA Yes NA 
no statistically 
significant difference 
0.03 
(D) 1 (D) 0.999 (D) D (1) 2.78 1.052 0.0002 . 0 . 
H202 17 48703688 C A NM_018896:c.6710C>A:p.Pro2237His NA Yes NA 
no statistically 
significant difference 
0.02 
(D) 0.994 (D) 0.974 (D) N (1) 4.32 2.484 0.0023 0.0002 0.0005 0.0003 
K087 17 48692795 C A NM_018896:c.4833C>A:p.His1611Gln NA Yes NA 
no statistically 
significant difference 
0.79 
(T) 0.999 (D) 0.993 (D) D (1) 4.75 2.17 . . . . 
7909 17 48677170 C A NM_018896:c.3640C>A:p.Pro1214Thr NA Yes NA NT 
0.4 
(T) 0.042 (B) 0.07 (B) N (1) 0.264 -0.055 . . . . 
SAL-REB-
399-400 17 48701820 C T NM_018896:c.6329C>T:p.Thr2110Ile NA Yes NA NT 
0.22 
(T) 0.43 (B) 0.24 (B) N (1) 2.88 1.338 . . . . 
AAD-BOR-
SAR-565-
012 17 48678124 G A NM_018896:c.3728G>A:p.Arg1243Gln NA Yes NA NT 
0.06 
(T) 0.999 (D) 0.98 (D) N (1) 5.46 2.569 0.005 0.001 0.0001 . 
AAD-SAL-
MAR-931-
001 17 48650036 G T NM_018896:c.868G>T:p.Gly290Trp No Yes NA NT 
0.02 
(D) 1 (D) 1 (D) D (1) 5.36 2.541 . . . . 
AAD-LIL-
SEP-246-
001 17 48673978 G A NM_018896:c.3035G>A:p.Gly1012Asp No Yes NA NT 
0.48 
(T) 1 (D) 0.999 (D) D (0.869) 4.14 2.375 0.0003 . 0.0001 0.0002 
AAD-STR-
ALB-916-
001 17 48703471 C T NM_018896:c.6493C>T:p.Arg2165Trp 
Missense 
monoallelic 
VUS in POLG  Yes NA NT 
0.02 
(D) 1 (D) 0.958 (D) N (0.996) 4.3 1.217 0 . 0 . 
AAD-GRE-
CUI-568-
014 17 48649991 C T NM_018896:c.823C>T:p.Arg275Cys 
Missense 
VUS in 
REEP1  Yes 
Present in 
unaffected 
mother NT 
0.01 
(D) 1 (D) 0.999 (D) N (0.99) 4.37 1.234 0.0004 . 0.0001 . 
  Variants of Unknown Significance AND pathogenic variant in another gene involved in ADCA 
AAD-BOR-
BAR-414-
003 17 48685335 C T NM_018896:c.4660C>T:p.Arg1554Trp 
Frameshift 
in CACNA1A 
(to confirm) Yes NA NT 
0.01 
(D) 1 (D) 0.997 (D) D (1) 3.71 2.196 0.0001 . 0 . 
AAD-SAL-
JAC-070-
007 
17 48674121 G A NM_018896:c.3095G>A:p.Arg1032Gln 
Frameshift 
in CACNA1A, 
missense 
monoallelic 
VUS in POLG 
(to confirm) Yes NA NT 
0.27 
(T) 0.88 (P) 0.329 (B) N (0.867) 0.624 -0.086 . . . . 
 
 Table S5. Characteristics of other CACNA1G variants found by panel sequencing. 
Summary of characteristics and pathogenicity evidences for all CACNA1G variants encompassed by panel sequencing. All scores are described in Table S2. No other 
variant than p.Arg1715His could lead to a definite conclusion regarding its pathogenicity, due to lack of other affected for segregation confirmation, or lack of           
functional proof. Only one other variant, p.Gly290Trp, is predicted pathogenic by all in silico softwares and is never present in public databases. No variant is located 
nearby p.Arg1715His, nor in S4 segments, regardless of the domain. All variants were therefore classified as variant of unknown significance (VUS).4 
Chr: Chromosome 
NA: not available 
NT: not tested 
Ref / Alt: reference and alternative base 
VUS: variant of unknown significance (ACMG class 3) 
 
Supplemental Table S6 
 
  WT   His1611Gln   Arg1068Cys   Pro2273His   
  Mean±SEM n Mean±SEM n Mean±SEM n Mean±SEM n 
Current density (pA/pF) -74.58±11.18 19 -43.47±13.35 4 -92.3±22.12 9 -68.76±16.79 6 
V1/2 act (mV) -47.2±0.65 18 -45.61±0.27 4 -47.01±0.63 8 -44.89±0.88 6 
K Vact (mV) 4.761±0.14 18 5.08±0.17 4 4.87±0.26 8 4.911±0.19 6 
V1/2inact (mV) -70.91±0.48 15 -70.07±0.39 4 -72.61±1.19 9 -69.54±0.46 6 
K Vinac (mV) 4.29±0.07 15 3.96±0.03 4 4.50±0.19 9 4.7±0.22 6 
τ act at -40 mV (ms) 4.38±0.39 10 4.15±0.28 4 3.59±0.19 4 3.94±0.28 5 
τ inact at -40 mV (ms) 16.27±0.77 10 17.03±1.59 4 13.8±0.96 4 15.45±0.53 5 
recovery (ms) 105.1±9.48 12 103.5±7.08 4 81.45±3.18 4 91.69±3.41 5 
τ deact at -70mv (ms) 3.87±0.25 8 3.65±0.33 3 3.18±0.148 4 3.44±0.29 6 
 
 
Table S6. Electrophysiological properties of additional Cav3.1 variants.  
V1/2 represents the half-activation and respectively half inactivation potential, K the slope factor, τact τinact and τdeact the activation, inactivat ion and respectively 
deactivation kinetics. n is the number of cells. No statistically significant differences were seen between the WT and the different variants presented in this table.  
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